The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease
Abstract
OBJECTIVE: Pulmonary disease (PD) caused by Mycobacterium avium complex (MAC) is increasing worldwide. We conducted a systematic review of studies that include microbiologic outcomes to evaluate current macrolide‐based treatment regimens. METHODS: We searched literature published before April 2017 by using the MEDLINE, Cochrane, and Embase databases. Risk of bias in randomized trials was assessed using the Cochrane tool. RESULTS: We retrieved 333 citations and evaluated 42 studies including 2,748 patients: 18 studies were retrospective chart reviews, 18 were prospective, and six were randomized. The weighted average proportion of sputum culture conversions in macrolide‐containing regimens after subtracting posttreatment microbiologic recurrences was 52.3% (95% CI, 44.7%‐59.9%). Using the triple‐drug regimens recommended by the American Thoracic Society (ATS) achieved treatment success in 61.4% (95% CI, 49.7%‐72.5%), which further increased to 65.7% (95% CI, 53.3%‐77.4%) when drugs were taken for at least 1 year by patients who were macrolide susceptible and had previously untreated MAC. The overall risk of bias was low in five of the six randomized trials. However, selective outcome reporting because of a posteriori exclusion of initially included patients (14.0%), uncompleted treatment (17.6%), and inconsistent use of outcome parameters (17 definitions of treatment success) hampered the comparison of nonrandomized trials. CONCLUSIONS: To date, randomized studies on treatment outcome in patients with MAC PD are scarce. Long‐term treatments with ATS‐recommended regimens for patients who are macrolide susceptible are superior to other macrolide‐based therapies. A standardized definition of treatment success and genotypic distinction between reinfection and relapse by means of pretreatment and posttreatment identification of MAC species in cases of microbiologic recurrences may help to optimize evaluation of treatment regimens in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Cited by
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00535-2020 · Cited by 924
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa241 · Cited by 890
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1125 · Cited by 786
Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases
Sharma, S. K., & Upadhyay, V. (2020) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_902_20 · Cited by 255
Metadata
- Authors
- Diel, R., Nienhaus, A., Ringshausen, F. C., Richter, E., Welte, T., Rabe, K. F., & Loddenkemper, R.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 153
- Issue
- 4
- Pages
- 888-921
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2787709298
- Cited by
- 172
- References
- 1
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. https://app.cochat.ai/papers/10.1016/j.chest.2018.01.024
- The paper
- Diel, R., Nienhaus, A., Ringshausen, F. C., Richter, E., Welte, T., Rabe, K. F., & Loddenkemper, R. (2018). Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. Chest. https://doi.org/10.1016/j.chest.2018.01.024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.